Trophoblast Cell Surface Antigen-2: A Promising Biomarker for Penile Squamous Cell Carcinoma

What is it about?

The study evaluates the potential utility of antibody-drug conjugates targeting TROP-2 in patients with primary penile squamous cell carcinoma (PSCC), patients with recurrence (REC cohort), and patient-matched distant metastases (MET cohort). The study also assesses the potential use of TROP-2 as a predictive non-invasive biomarker in PSCC. The results show that TROP-2 is significantly increased in primary and recurrent PSCC compared to cancer-free controls. Immunohistochemical analysis reveals that most of the PRIM cohort, as well as all patients in the REC and MET cohorts, exhibit moderate to strong membranous TROP-2 expression. The study suggests that TROP-2 can be used as a non-invasive biomarker for diagnosing PSCC and potentially selecting patients for TROP-2-targeted ADC therapy.

Featured Image

Why is it important?

This research is important because it evaluates the potential utility of antibody-drug conjugates targeting trophoblast cell surface antigen-2 (TROP-2) in patients with primary penile squamous cell carcinoma (PSCC), patients with recurrence (REC cohort), and patient-matched distant metastases (MET cohort), and assesses the potential use of TROP-2 as a predictive non-invasive biomarker in PSCC. The study found that TROP-2 is frequently overexpressed in primary, recurrent and metastatic PSCC, which supports further studies on TROP-2 as a diagnostic and therapeutic target in PSCC. Key Takeaways: 1. TROP-2 is frequently overexpressed in primary, recurrent and metastatic PSCC. 2. TROP-2 can be used as a non-invasive biomarker for diagnosing PSCC and potentially selecting patients for TROP-2-targeted ADC therapy. 3. Antibody-drug conjugates targeting TROP-2 have shown significant clinical effectiveness in treating solid tumours, including breast, lung, and bladder cancers.